Hims & Hers Health (HIMS) Projected to Post Quarterly Earnings on Monday

Key Points

• Hims & Hers Health is set to release its Q2 2025 earnings results on Monday, August 4th, with analysts expecting earnings of $0.17 per share and revenue of $550.06 million.
• In the previous quarter, the company reported $0.20 EPS, surpassing estimates, and a 110.7% year-over-year revenue increase to $586.01 million.
• A hedge fund recently acquired shares of Hims & Hers Health, with 63.52% of the stock now owned by institutional investors, indicating strong interest in the company.

Hims & Hers Health (NYSE:HIMS - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Monday, August 4th. Analysts expect the company to announce earnings of $0.17 per share and revenue of $550.06 million for the quarter. Hims & Hers Health has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The company had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same period in the prior year, the business posted $0.05 earnings per share. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $2.89 during midday trading on Thursday, hitting $68.42. 26,946,184 shares of the stock were exchanged, compared to its average volume of 33,816,809. Hims & Hers Health has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a fifty day simple moving average of $53.21 and a 200 day simple moving average of $43.51. The firm has a market cap of $15.31 billion, a P/E ratio of 99.56, a P/E/G ratio of 2.22 and a beta of 2.02.

Analyst Ratings Changes

A number of research analysts recently issued reports on HIMS shares. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Morgan Stanley reissued an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Truist Financial lifted their price objective on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $39.83.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,572 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $58.70, for a total value of $150,976.40. Following the completion of the transaction, the insider directly owned 155,593 shares of the company's stock, valued at $9,133,309.10. This represents a 1.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 2,100 shares of the company's stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $57.52, for a total transaction of $120,792.00. Following the completion of the transaction, the insider directly owned 278,654 shares of the company's stock, valued at approximately $16,028,178.08. The trade was a 0.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 737,704 shares of company stock valued at $40,644,035 in the last 90 days. 13.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

An institutional investor recently bought a new position in Hims & Hers Health stock. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,018 shares of the company's stock, valued at approximately $30,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.